Table of Contents
International Journal of Molecular Imaging
Volume 2011 (2011), Article ID 874585, 8 pages
http://dx.doi.org/10.1155/2011/874585
Research Article

[ 𝟏 𝟖 F ]Fluoro-2-Deoxy-D-Glucose Incorporation by MCF-7 Breast Tumour Cells In Vitro Is Modulated by Treatment with Tamoxifen, Doxorubicin, and Docetaxel: Relationship to Chemotherapy-Induced Changes in ATP Content, Hexokinase Activity, and Glucose Transport

1School of Medical Sciences (Biomedical Physics), Aberdeen Biomedical Imaging Centre (ABIC), University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
2John Mallard PET Centre, Aberdeen Biomedical Imaging Centre (ABIC), University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK

Received 15 July 2010; Revised 30 August 2010; Accepted 24 September 2010

Academic Editor: Adriaan Anthonius Lammertsma

Copyright © 2011 R. I. Sharma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Cancer Society, Cancer facts & figures 2005, http://www.cancer.org/acs/groups/content/@nho/documents/document/caff2005f4pwsecuredpdf.pdf.
  2. M. Cianfrocca and W. J. Gradishar, “Controversies in the therapy of early stage breast cancer,” Oncologist, vol. 10, no. 10, pp. 766–779, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. C. A. Saurel, T. A. Patel, and E. A. Perez, “Changes to adjuvant systemic therapy in breast cancer: a decade in review,” Clinical Breast Cancer, vol. 10, no. 3, pp. 196–208, 2010. View at Publisher · View at Google Scholar · View at PubMed
  4. C. R. Meier and H. Jick, “Tamoxifen and risk of idiopathic venous thromboembolism,” British Journal of Clinical Pharmacology, vol. 45, no. 6, pp. 608–612, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Grana, “Adjuvant aromatase inhibitor therapy for early breast cancer: a review of the most recent data,” Journal of Surgical Oncology, vol. 93, no. 7, pp. 585–592, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. N. C. Krak, O. S. Hoekstra, and A. A. Lammartsma, “Measuring response to chemotherapy inlocally advanced breast cancer: methodological considerations,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, pp. S103–S111, 2004. View at Google Scholar
  7. J. D. Schwarz, M. Bader, L. Jenicke, G. Hemminger, F. Jänicke, and N. Avril, “Early prediction of response to chemotherapy in metastatic breast cancer using sequential18F-FDG PET,” Journal of Nuclear Medicine, vol. 46, no. 7, pp. 1144–1150, 2005. View at Google Scholar · View at Scopus
  8. G. M. McDermott, A. Welch, R. T. Staff et al., “Monitoring primary breast cancer throughout chemotherapy using FDG-PET,” Breast Cancer Research and Treatment, vol. 102, no. 1, pp. 75–84, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. E. Mortimer, F. Dehdashti, B. A. Siegel, K. Trinkaus, J. A. Katzenellenbogen, and M. J. Welch, “Metabolic flare: indicator of hormone responsiveness in advanced breast cancer,” Journal of Clinical Oncology, vol. 19, no. 11, pp. 2797–2803, 2001. View at Google Scholar · View at Scopus
  10. T. A. D. Smith, “Facilitative glucose transporter expression in human cancer tissue,” British Journal of Biomedical Science, vol. 56, no. 4, pp. 285–292, 1999. View at Google Scholar · View at Scopus
  11. T. A. D. Smith, R. I. Sharma, A. M. Thompson, and F. E. M. Paulin, “Tumor F18 -FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro,” Journal of Nuclear Medicine, vol. 47, no. 9, pp. 1525–1530, 2006. View at Google Scholar · View at Scopus
  12. C. Caracó, L. Aloj, L.-Y. Chen, J. Y. Chou, and W. C. Eckelman, “Cellular release of [F18 ]2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system,” The Journal of Biological Chemistry, vol. 275, no. 24, pp. 18489–18494, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. M. Engles, S. A. Quarless, E. Mambo, T. Ishimori, S. Y. Cho, and R. L. Wahl, “Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy,” Journal of Nuclear Medicine, vol. 47, no. 4, pp. 603–608, 2006. View at Google Scholar · View at Scopus
  14. M. L. Macheda, S. Rogers, and J. D. Best, “Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer,” Journal of Cellular Physiology, vol. 202, no. 3, pp. 654–662, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. T. A. D. Smith, “Mammalian hexokinases and their abnormal expression in cancer,” British Journal of Biomedical Science, vol. 57, no. 2, pp. 170–178, 2000. View at Google Scholar · View at Scopus
  16. H. A. Bawadi, R. R. Bansode, A. Trappey II, R. E. Truax, and J. N. Losso, “Inhibition of Caco-2 colon, MCF-7 and Hs578T breast, and DU 145 prostatic cancer cell proliferation by water-soluble black bean condensed tannins,” Cancer Letters, vol. 218, no. 2, pp. 153–162, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. C. A. Smith and C. L. Hinman, “A cyclic peptide, L1AD3, induces early signs of apoptosis in human leukemic T-cells lines,” Journal of Biochemical and Molecular Toxicology, vol. 18, no. 4, pp. 204–220, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. Y.-M. Fu, H. Zhang, M. Ding et al., “Selective amino acid restriction targets mitochondria to induce apoptosis of androgen-independent prostate cancer cells,” Journal of Cellular Physiology, vol. 209, no. 2, pp. 522–534, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. E. K. Cloherty, K. B. Levine, C. Graybill, and A. Carruthers, “Cooperative nucleotide binding to the human erythrocyte sugar transporter,” Biochemistry, vol. 41, no. 42, pp. 12639–12651, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Miccoli, S. Oudard, F. Sureau, F. Poirson, B. Dutrillaux, and M.-F. Poupon, “Intracellular pH governs the subcellular distribution of hexokinase in a glioma cell line,” Biochemical Journal, vol. 313, no. 3, pp. 957–962, 1996. View at Google Scholar · View at Scopus
  21. H. Toyama, M. Ichise, J.-S. Liow et al., “Absolute quantification of regional cerebral glucose utilization in mice by F18 -FDG small animal PET scanning and 2-C14 -DG autoradiography,” Journal of Nuclear Medicine, vol. 45, no. 8, pp. 1398–1405, 2004. View at Google Scholar · View at Scopus
  22. D. Rivenzon-Segal, R. Margalit, and H. Degani, “Glycolysis as a metabolic marker in orthotopic breast cancer, monitored by in vivo C13 MRS,” American Journal of Physiology, vol. 283, no. 4, pp. E623–E630, 2002. View at Google Scholar · View at Scopus
  23. P. Burgman, J. A. O'Donoghue, J. L. Humm, and C. C. Ling, “Hypoxia-induced increase in FDG uptake in MCF7 cells,” Journal of Nuclear Medicine, vol. 42, no. 1, pp. 170–175, 2001. View at Google Scholar · View at Scopus
  24. M. Reivich, A. Alavi, and A. Wolf, “Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [F18 ]fluorodeoxyglucose and [C11 ]deoxyglucose,” Journal of Cerebral Blood Flow and Metabolism, vol. 5, no. 2, pp. 179–192, 1985. View at Google Scholar
  25. T. Takei, Y. Kuge, S. Zhao et al., “Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of T99mc-Annexin V, F18 -FDG, and histological evaluation,” The Journal of Nuclear Medicine, vol. 46, pp. 794–799, 2005. View at Google Scholar
  26. T. A. D. Smith and M. G. Blaylock, “Treatment of breast tumor cells in vitro with the mitochondrial membrane potential dissipater valinomycin increases F18 -FDG incorporation,” Journal of Nuclear Medicine, vol. 48, no. 8, pp. 1308–1312, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. R. S. Brown, J. Y. Leung, S. J. Fisher, K. A. Frey, S. P. Ethier, and R. L. Wahl, “Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important?” Journal of Nuclear Medicine, vol. 36, no. 10, pp. 1854–1861, 1995. View at Google Scholar · View at Scopus
  28. K. Kyoichi, E. Masahiro, A. Masato et al., “Biologic correlation of 2-[F18 ]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors,” Journal of Clinical Oncology, vol. 28, pp. 3746–3753, 2010. View at Google Scholar